Analysts await Kura Oncology, Inc. (NASDAQ:KURA) to report earnings on Mar, 17 for the fiscal quarter ending Dec 2015.

They expect $-0.44 EPS, down 100% or $0.44 from last year’s $n/a per share.

At the moment 4 analysts are watching Kura Oncology, Inc. (NASDAQ:KURA), 3 rate it “Buy”, 1 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 2 analysts have a mean sales target of 0.00 million. For the quarter ending Jun-16, 2 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 2 analysts have a mean target of 0.00 million.

In terms of earnings per share, 2 analysts have a -0.52 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.56 EPS mean target and for the quarter ending Jun-16 there are 3 estimates of -2.85 EPS.

The biggest institutional shareholders in Kura Oncology, Inc. include EcoR1 Capital, LLC which owns 2 million shares in the company valued at $20.58 million. ARCH Venture Partners is the second biggest holder with 2 million shares currently valued at 15.86 million whilst Fidelity Management and Research Company has 2 million shares valued at 0.00 million.

Total shares held by institutions as of the most recent company filings are 8,844,307 with a reported 999,300 bought and 0 sold. These holdings make up 7.87% of the company’s outstanding shares.

The stock increased 6.67% or $0.27 during the last trading session, hitting $4.96. Kura Oncology, Inc. (NASDAQ:KURA) has fallen 202.42% over the past 6 months and is downtrending.